Tumor microenvironment: Influence on cancer treatment.
DOI:
https://doi.org/10.35954/SM2025.44.1.3.e401Keywords:
Cytokines, Tumor Microenvironment, Neoplasms, Chemokines.Abstract
The present review addresses the tumor microenvironment as a therapeutic target in cancer treatment.
We discuss both its composition and its influence on tumor progression and resistance, as well as different therapeutic strategies aimed at its modulation. Understanding the intricate interactions within the tumor microenvironment is not only fundamental to understanding cancer biology, but also key to the future of cancer therapies, offering new hope in the fight against this devastating disease.
This article was approved by the Editorial Committee.
Received for review: December 2024.
Accepted for publication: December 2024.
Correspondence: Faculty of Sciences. Mataojo 2055, C.P. 11400. Montevideo, Uruguay. Tel: (+598) 099472572.
Contact e-mail: pcabral@cin.edu.uy
Downloads
Metrics
References
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 2023 May; 12(10):11149-11165. https://doi.org/10.1002/cam4.5698 PMID: 36807772; PMCID: PMC10242329.
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 2021 May; 221:107753. https://doi.org/10.1016/j.pharmthera.2020.107753 PMID: 33259885; PMCID: PMC8084948.
Dzobo K, Senthebane DA, Dandara C. The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers (Basel) 2023 Jan 6; 15(2):376. https://doi.org/10.3390/cancers15020376 PMID: 36672326; PMCID: PMC9856874.
Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 2020; 18(59). https://doi.org/10.1186/s12964-020-0530-4
Baghy K, Ladányi A, Reszegi A, Kovalszky I. Insights into the tumor microenvironment-components, functions and therapeutics. Int J Mol Sci 2023 Dec 15; 24(24):17536. https://doi.org/10.3390/ijms242417536 PMID: 38139365; PMCID: PMC10743805.
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 2023 Mar 13; 41(3):374-403. https://doi.org/10.1016/j.ccell.2023.02.016 PMID: 36917948.
Lu C, Liu Y, Ali NM, Zhang B, Cui X. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol 2023 Jan 19; 13:1039260. https://doi.org/10.3389/fimmu.2022.1039260 PMID: 36741415; PMCID: PMC9893925.
Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett 2020 Feb 1; 470:126-133. https://doi.org/10.1016/j.canlet.2019.11.009 Epub 2019 Nov 12. PMID: 31730903.
Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol 2020 Dec 3; 11:583084. https://doi.org/10.3389/fimmu.2020.583084 Erratum in: Front Immunol 2021 Dec 10; 12:775758. https://doi.org/10.3389/fimmu.2021.775758 PMID: 33365025; PMCID: PMC7751482.
Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting. Vaccines (Basel) 2016 Aug 6; 4(3):28. https://doi.org/10.3390/vaccines4030028 PMID: 27509527; PMCID: PMC5041022.
Wright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-associated fibroblasts: Master tumor microenvironment modifiers. Cancers (Basel) 2023 Mar 22; 15(6):1899. https://doi.org/10.3390/cancers15061899 PMID: 36980785; PMCID: PMC10047485.
Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 2017 Feb 8; 45(1):229-236. https://doi.org/10.1042/BST20160387 PMID: 28202677; PMCID: PMC5371349.
Zhao Z, Li T, Sun L, Yuan Y, Zhu Y. Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomed Pharmacother 2023 Oct; 166:115425. https://doi.org/10.1016/j.biopha.2023.115425 Epub 2023 Sep 4. PMID: 37660643.
Arima Y, Matsueda S, Saya H. Significance of cancer-associated fibroblasts in the interactions of cancer cells with the tumor microenvironment of heterogeneous tumor tissue. Cancers (Basel) 2023 Apr 28; 15(9):2536. https://doi.org/10.3390/cancers15092536 PMID: 37174001; PMCID: PMC10177529.
Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res 2020 Sep 30; 39(1):204. https://doi.org/10.1186/s13046-020-01709-5 PMID: 32993787; PMCID: PMC7526376.
Feng Y, Ye Z, Song F, He Y, Liu J. The role of TAMs in tumor microenvironment and new research progress. Stem Cells Int 2022 Aug 15; 2022:5775696. https://doi.org/10.1155/2022/5775696 Retraction in: Stem Cells Int 2024 Jan 24; 2024:9893249. https://doi.org/10.1155/2024/9893249 PMID: 36004381; PMCID: PMC9395242.
He M, He Q, Cai X, Chen Z, Lao S, Deng H, et al. Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances. Transl Lung Cancer Res 2021 May; 10(5):2252-2277. https://doi.org/10.21037/tlcr-21-40 PMID: 34164274; PMCID: PMC8182726.
Henke E, Nandigama R, Ergün S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 2020 Jan 31; 6:160. https://doi.org/10.3389/fmolb.2019.00160 PMID: 32118030; PMCID: PMC7025524.
Du W, Xia X, Hu F, Yu J. Extracellular matrix remodeling in the tumor immunity. Front Immunol 2024 Jan 25; 14:1340634. https://doi.org/10.3389/fimmu.2023.1340634 PMID: 38332915; PMCID: PMC10850336.
Tan Y, Wang M, Zhang Y, Ge S, Zhong F, Xia G, et al. Tumor-associated macrophages: A potential target for cancer therapy. Front Oncol 2021 Jun 10; 11:693517. DOI: 10.3389/fonc.2021.693517. PMID: 34178692; PMCID: PMC8222665.
Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis 2023 Mar 30; 11(1):234-251. https://doi.org/10.1016/j.gendis.2023.02.039 PMID: 37588219; PMCID: PMC10425810.
Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov 2024 Aug 2; 14(8):1375-1388. https://doi.org/10.1158/2159-8290.CD-24-0002 PMID: 39091205; PMCID: PMC11294818.
Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by exosomes. Mol Cancer 2019 Mar 30; 18(1):58. https://doi.org/10.1186/s12943-019-0970-x PMID: 30925921; PMCID: PMC6441190.
Bouleftour W, Rowinski E, Louati S, Sotton S, Wozny AS, Moreno-Acosta P, et al. A Review of the role of hypoxia in radioresistance in cancer therapy. Med Sci Monit 2021 Nov 3; 27:e934116. https://doi.org/10.12659/MSM.934116 PMID: 34728593; PMCID: PMC8573967.
Mendoza EN, Ciriolo MR, Ciccarone F. Hypoxia-induced reactive oxygen species: Their role in cancer resistance and emerging therapies to overcome It. Antioxidants 2025; 14(94). https://doi.org/10.3390/antiox14010094
Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Front Immunol 2022 May 3; 13:874589. https://doi.org/10.3389/fimmu.2022.874589 PMID: 35592338; PMCID: PMC9110638.
Sarkar T, Dhar S, Sa G. Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape. Curr Res Immunol 2021 Aug 28; 2:132-141. https://doi.org/10.1016/j.crimmu.2021.08.002 PMID: 35492399; PMCID: PMC9040151.
Khan SU, Khan MU, Azhar Ud Din M, Khan IM, Khan MI, Bungau S, et al. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. Front Immunol 2023 Apr 17; 14:1166487. https://doi.org/10.3389/fimmu.2023.1166487 PMID: 37138860; PMCID: PMC10149956.
Zhao J, Chen J, Li C, Xiang H, Miao X. Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery. Eur J Pharm Biopharm 2024 Oct; 203:114474. https://doi.org/10.1016/j.ejpb.2024.114474 PMID: 39191305.
Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Front Immunol 2020 Aug 25; 11:1956. https://doi.org/10.3389/fimmu.2020.01956 PMID: 32983126; PMCID: PMC7477085.
Tokizaki S, Podyma-Inoue KA, Matsumoto T, Takahashi K, Kobayashi M, Ibi H, et al. Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks. Cancer Sci 2024 Jan; 115(1):211-226. https://doi.org/10.1111/cas.16006 PMID: 37972575; PMCID: PMC10823284.
Siddiqui JA, Pothuraju R, Khan P, Sharma G, Muniyan S, Seshacharyulu P, et al. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia. Cytokine Growth Factor Rev 2022 Apr; 64:71-83. https://doi.org/10.1016/j.cytogfr.2021.11.002 Epub 2021 Nov 17. PMID: 34836750; PMCID: PMC8957514.
Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci) 2018 Sep-Dec;6(3-4):79-100. https://doi.org/10.1142/S2339547818300020 Epub 2019 Jan 11. PMID: 30713991; PMCID: PMC6352312.
Nema R. An omics-based tumor microenvironment approach and its prospects. Rep Pract Oncol Radiother 2024 Dec 4; 29(5):649-650. https://doi.org/10.5603/rpor.102823 PMID: 39759552; PMCID: PMC11698559.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Salud Militar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
